End-Stage Liver Disease

End-stage liver disease refers to the point at which the liver has sustained irreversible damage so extensive that it can no longer perform its essential functions adequately. It is not a single disease in itself — it is the final common pathway of many different liver conditions, all of which, if left untreated or uncontrolled, eventually destroy enough liver tissue to reach this threshold.

The liver is a resilient organ. It can regenerate, compensate, and adapt in ways that most organs cannot. Early liver damage often goes unnoticed because the liver quietly manages despite the injury. But every liver has a limit. When scarring — known as fibrosis — accumulates to the point where normal architecture is replaced by non-functional scar tissue throughout the organ, the liver crosses from a state of compensation into decompensation.

The severity of end-stage liver disease is measured using the MELD score — Model for End-Stage Liver Disease — a numerical value calculated from blood test results that reflects how urgently a patient needs a liver transplant. Scores range from six to forty, with higher scores indicating more severe disease and a higher short-term mortality risk without transplantation.

Patients with end-stage liver disease generally fall into one of two categories:

Decompensated Liver Disease
Decompensated liver disease is the defining feature of end-stage disease. At this point the liver can no longer filter toxins from the blood, produce the proteins needed for clotting and immune function, regulate fluid balance, or process nutrients and medications properly. Cirrhotic patients in this category experience an acute deterioration in liver function characterised by severe symptoms and life-threatening complications — including ascites, hepatic encephalopathy, variceal bleeding, and spontaneous bacterial peritonitis — that significantly increase the risk of mortality. The consequences of this failure ripple through every organ system in the body, and the window for intervention narrows considerably without definitive treatment such as liver transplantation.

Compensated Liver Disease
In compensated liver disease, the liver has progressed to cirrhosis — the final stage of liver fibrosis — yet still retains enough functional reserve to manage its day-to-day responsibilities without obvious clinical failure. Patients are often entirely asymptomatic or experience only mild, non-specific symptoms such as fatigue or reduced appetite. This is precisely what makes compensated cirrhosis deceptive — a person can feel relatively well while significant structural damage is already present. It is also important to note that some patients with compensated liver disease can develop hepatocellular carcinoma (liver cancer) even before decompensation occurs, which is why regular surveillance with ultrasound and AFP blood tests every six months is strongly recommended for all cirrhotic patients regardless of how well they feel.

The complications of end-stage liver disease are numerous, serious, and often interconnected. Managing them and preventing them from becoming life-threatening — is the central challenge of caring for patients with this condition.

• Ascites is the accumulation of fluid in the abdominal cavity and is one of the most common and visible complications. It develops because the failing liver produces insufficient albumin to keep fluid inside blood vessels, while elevated portal vein pressure drives fluid out of the vascular system into the abdomen. Ascites causes significant discomfort, restricts breathing, and creates a risk of spontaneous bacterial peritonitis, a potentially fatal infection of the abdominal fluid.
• Hepatic encephalopathy occurs when the liver can no longer clear ammonia and other toxins from the blood. These substances accumulate and affect brain function, causing symptoms that range from mild confusion and forgetfulness to profound disorientation, altered consciousness, and coma. Precipitating factors include infection, constipation, gastrointestinal bleeding, and missed medications all of which can tip a previously stable patient into acute encephalopathy.
• Portal hypertension elevated blood pressure in the portal vein caused by resistance from the scarred liver has cascading effects throughout the body. It drives ascites, causes the spleen to enlarge (leading to reduced platelet counts and increased bleeding risk), and forces blood to find alternative pathways through smaller vessels that are not designed to handle the pressure.
• Oesophageal and gastric varices are enlarged, fragile veins that develop in the oesophagus and stomach as blood bypasses the obstructed liver through alternative channels. These veins can rupture without warning, causing catastrophic upper gastrointestinal bleeding one of the most feared and life-threatening emergencies in hepatology.
• Hepatorenal syndrome is a serious deterioration in kidney function that occurs in the context of advanced liver disease. The kidneys respond to the circulatory changes caused by liver failure by constricting their blood supply, leading to progressive renal failure. Without intervention typically liver transplantation. it carries a very poor prognosis.
• Spontaneous bacterial peritonitis (SBP) is an infection of ascitic fluid that occurs without any obvious source of contamination. It develops because the failing liver can no longer maintain the immune defences of the gut wall, allowing bacteria to translocate from the intestines into the abdominal fluid. SBP can be life-threatening if not diagnosed and treated promptly with antibiotics.
• Hepatocellular carcinoma (HCC) liver cancer develops in a significant proportion of patients with cirrhosis, with a risk of approximately two to four percent per year. Regular surveillance with ultrasound and AFP measurement every six months is recommended for all patients with cirrhosis.
• Coagulopathy impaired blood clotting develops because the failing liver cannot produce adequate clotting factors. This increases the risk of bleeding from any cause and complicates surgical and procedural interventions.

The symptoms of end-stage liver disease reflect the multiple systems affected by a liver that is no longer functioning adequately.

Jaundice — yellowing of the skin and whites of the eyes — occurs when the liver cannot process bilirubin, a yellow pigment produced by the breakdown of red blood cells. It is often accompanied by dark, tea-coloured urine and pale, clay-coloured stools.

Profound fatigue and weakness are among the most debilitating and consistent symptoms. The fatigue of liver failure is different from ordinary tiredness — it is bone-deep, unresponsive to rest, and often accompanied by muscle wasting as the body breaks down muscle protein in the absence of adequate liver-synthesised nutrients.

Abdominal swelling from ascites causes visible distension of the abdomen, discomfort, and a sensation of fullness. In severe cases, the abdomen becomes tense and the accumulated fluid can be detected by physical examination.

Confusion and cognitive changes from hepatic encephalopathy can range from subtle — slight forgetfulness, difficulty concentrating, mood changes — to severe, with marked disorientation, slurred speech, and loss of consciousness.

Bleeding and bruising occur easily because of reduced clotting factor production. Minor cuts bleed longer than expected, and bruises appear from minimal trauma.

Spider angiomas — small, spider-like blood vessel formations visible on the skin, particularly on the chest and face — are a classic physical sign of chronic liver disease. Palmar erythema — redness of the palms — is another. In men, gynaecomastia (breast tissue enlargement) and testicular atrophy can develop due to hormonal imbalances the failing liver can no longer regulate.

Itching (pruritus) is particularly associated with bile duct-related liver diseases and results from bile salt accumulation in the skin.

Diagnosing end-stage liver disease and accurately assessing its severity requires a combination of clinical assessment, laboratory tests, and imaging.

Blood tests form the foundation of assessment. Liver function tests — including bilirubin, albumin, and liver enzymes (ALT, AST, ALP, GGT) — provide a broad picture of liver health. Coagulation tests (particularly the INR — International Normalised Ratio) assess clotting factor production. A full blood count typically shows low platelet counts due to an enlarged spleen. Kidney function tests (creatinine, urea) monitor for hepatorenal syndrome.

The MELD score (Model for End-Stage Liver Disease) is the most widely used tool for quantifying disease severity and predicting short-term mortality. It is calculated from three blood values — creatinine, bilirubin, and INR — and produces a score from 6 to 40. Higher scores indicate more severe disease and higher short-term mortality risk. The MELD score is used internationally to prioritise patients on liver transplant waiting lists.

The Child-Pugh score is an older but still widely used scoring system that incorporates bilirubin, albumin, INR, the presence of ascites, and the degree of encephalopathy to classify liver disease into three grades of severity — A (compensated), B (moderate decompensation), and C (severe decompensation).

Ultrasound imaging assesses liver size, shape, and texture, detects ascites, evaluates portal vein blood flow, and screens for liver tumours. It is the primary surveillance tool for hepatocellular carcinoma in patients with cirrhosis.

CT and MRI scans provide more detailed anatomical information when clinically indicated — particularly for surgical planning, characterisation of liver masses, or evaluation of vascular complications.

Liver biopsy, while the gold standard for assessing fibrosis stage, is rarely performed in patients with established end-stage liver disease because coagulopathy increases the bleeding risk, and the clinical picture is usually sufficiently clear without it.

Endoscopy (gastroscopy) is performed to screen for oesophageal and gastric varices in all patients diagnosed with cirrhosis. Finding varices guides decisions about preventive treatment.

Treatment of end-stage liver disease is not a single intervention — it is a complex, ongoing, multi-disciplinary effort to manage complications, preserve quality of life, slow progression where possible, and prepare suitable candidates for liver transplantation.

Managing ascites involves dietary sodium restriction — typically less than 2 grams of sodium per day — alongside diuretic medications, most commonly spironolactone and furosemide in combination. When ascites becomes refractory to diuretics, large-volume paracentesis — draining fluid from the abdomen using a needle — provides relief. A transjugular intrahepatic portosystemic shunt (TIPS) procedure can reduce portal pressure in selected patients and reduce the frequency of ascites recurrence.

Treating hepatic encephalopathy involves identifying and addressing precipitating factors (infection, bleeding, constipation) and using lactulose — a non-digestible sugar that draws ammonia into the colon — to reduce ammonia levels. Rifaximin, a non-absorbable antibiotic, is used as maintenance therapy to prevent recurrent episodes.

Managing varices involves non-selective beta-blockers (carvedilol or propranolol) to reduce portal pressure and the risk of bleeding. Endoscopic band ligation — placing small elastic bands around varices during gastroscopy — is used both to treat acute variceal bleeding and to prevent it in patients with large, high-risk varices.

Treating infections, particularly spontaneous bacterial peritonitis, requires prompt antibiotic therapy. Long-term antibiotic prophylaxis is recommended for patients who have had a prior episode of SBP or whose ascitic fluid protein levels are very low.

Nutritional support is a frequently underestimated component of management. Patients with end-stage liver disease are often malnourished, with reduced muscle mass that worsens outcomes. High-protein diets (contrary to older, now-outdated advice), frequent small meals, and late-evening snacks are recommended to maintain muscle mass and liver glycogen stores.

Treating the underlying cause remains important even at advanced stages. Antiviral therapy for hepatitis B and C can slow or partially reverse fibrosis. Complete alcohol abstinence can stabilise or occasionally improve compensated cirrhosis of the liver. Managing diabetes and obesity reduces the progression of NASH-related disease.

While cirrhosis is the most common pathway, several specific diseases deserve mention as leading causes of progression to end-stage liver disease.

Chronic hepatitis B and C remain the most prevalent globally. Alcohol-related liver disease is the leading cause in many Western nations. NASH is the most rapidly growing cause worldwide, driven by metabolic syndrome.

Primary biliary cholangitis and primary sclerosing cholangitis are autoimmune bile duct diseases that progress relentlessly without treatment, with PSC in particular carrying a high risk of cholangiocarcinoma (bile duct cancer) alongside cirrhosis.

Hereditary haemochromatosis, if undiagnosed and untreated, leads to iron overload that destroys the liver over decades. Wilson's disease causes copper accumulation with a similar destructive trajectory. Alpha-1 antitrypsin deficiency — an underdiagnosed genetic condition — causes progressive liver damage from infancy through adulthood.

Budd-Chiari syndrome — obstruction of the hepatic veins draining blood from the liver — causes acute or chronic liver congestion that can progress rapidly to cirrhosis if untreated. Cardiac cirrhosis, resulting from chronic right-sided heart failure causing venous congestion of the liver, is an increasingly recognised cause in patients with long-standing cardiovascular disease.

The prognosis depends on disease severity, underlying cause, and whether transplantation is possible. Without a transplant, one-year mortality after first decompensation ranges from 20 to 57 percent, worsening with each subsequent episode. With transplantation, one-year survival reaches 85 to 90 percent and five-year survival 70 to 80 percent — with most patients returning to a normal, active life.

For those who are not transplant candidates, supportive care focuses on managing complications and maintaining quality of life, which can still be meaningfully extended with the right management. Above all, earlier intervention leads to better outcomes — patients referred to specialist care before reaching advanced decompensation have more options, better responses to treatment, and a stronger chance of a successful transplant.